WO1998016202A3 - Fusogenic liposome composition and method - Google Patents

Fusogenic liposome composition and method Download PDF

Info

Publication number
WO1998016202A3
WO1998016202A3 PCT/US1997/018838 US9718838W WO9816202A3 WO 1998016202 A3 WO1998016202 A3 WO 1998016202A3 US 9718838 W US9718838 W US 9718838W WO 9816202 A3 WO9816202 A3 WO 9816202A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
target cells
liposome
hydrophobic polymers
liposomes
Prior art date
Application number
PCT/US1997/018838
Other languages
French (fr)
Other versions
WO1998016202B1 (en
WO1998016202A2 (en
Inventor
Francis J Martin
Samuel Zalipsky
Original Assignee
Sequus Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequus Pharm Inc filed Critical Sequus Pharm Inc
Priority to AT97912775T priority Critical patent/ATE232086T1/en
Priority to AU49878/97A priority patent/AU715063B2/en
Priority to EP97912775A priority patent/EP0932391B1/en
Priority to CA002267904A priority patent/CA2267904C/en
Priority to JP51862998A priority patent/JP2001504093A/en
Priority to DK97912775T priority patent/DK0932391T3/en
Priority to IL12929297A priority patent/IL129292A0/en
Priority to DE69718924T priority patent/DE69718924T2/en
Priority to BR9712230-0A priority patent/BR9712230A/en
Publication of WO1998016202A2 publication Critical patent/WO1998016202A2/en
Publication of WO1998016202A3 publication Critical patent/WO1998016202A3/en
Publication of WO1998016202B1 publication Critical patent/WO1998016202B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation

Abstract

A fusogenic liposome composition for delivering a liposome-entrapped compound into the cytoplasm of a target cell is described. The liposomes have an outer surface coating of chemically releasable hydrophilic polymer chains which shield hydrophobic polymers on the liposomes outer surface. Release of the hydrophilic polymer chains exposes the hydrophobic polymers for interaction with outer cell membranes of the target cells to promote fusion of the liposome with the target cells. Also disclosed is a method for using the composition to deliver a compound to target cells, and a method for selecting suitable hydrophobic polymers for use in the composition.
PCT/US1997/018838 1996-10-11 1997-10-10 Fusogenic liposome composition and method WO1998016202A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AT97912775T ATE232086T1 (en) 1996-10-11 1997-10-10 FUSOGENIC LIPOSOME COMPOSITION AND METHODS
AU49878/97A AU715063B2 (en) 1996-10-11 1997-10-10 Fusogenic liposome composition and method
EP97912775A EP0932391B1 (en) 1996-10-11 1997-10-10 Fusogenic liposome composition and method
CA002267904A CA2267904C (en) 1996-10-11 1997-10-10 Fusogenic liposome composition and method
JP51862998A JP2001504093A (en) 1996-10-11 1997-10-10 Fusion liposome compositions and methods
DK97912775T DK0932391T3 (en) 1996-10-11 1997-10-10 Fusogenic liposome composition and method
IL12929297A IL129292A0 (en) 1996-10-11 1997-10-10 Fusogenic liposome composition and method
DE69718924T DE69718924T2 (en) 1996-10-11 1997-10-10 FUSOGENIC LIPOSOME COMPOSITION AND METHOD
BR9712230-0A BR9712230A (en) 1996-10-11 1997-10-10 Fusogenic liposome method and composition.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2826996P 1996-10-11 1996-10-11
US60/028,269 1996-10-11

Publications (3)

Publication Number Publication Date
WO1998016202A2 WO1998016202A2 (en) 1998-04-23
WO1998016202A3 true WO1998016202A3 (en) 1998-07-16
WO1998016202B1 WO1998016202B1 (en) 1998-09-03

Family

ID=21842486

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/018838 WO1998016202A2 (en) 1996-10-11 1997-10-10 Fusogenic liposome composition and method

Country Status (15)

Country Link
US (1) US5891468A (en)
EP (1) EP0932391B1 (en)
JP (1) JP2001504093A (en)
AT (1) ATE232086T1 (en)
AU (1) AU715063B2 (en)
BR (1) BR9712230A (en)
CA (1) CA2267904C (en)
DE (1) DE69718924T2 (en)
DK (1) DK0932391T3 (en)
ES (1) ES2191833T3 (en)
HK (1) HK1047550A1 (en)
IL (1) IL129292A0 (en)
PT (1) PT932391E (en)
TW (1) TW520297B (en)
WO (1) WO1998016202A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227917B2 (en) 2012-08-13 2016-01-05 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US20070036722A1 (en) * 1996-10-28 2007-02-15 Pal Rongved Separation processes
CA2271325A1 (en) * 1996-11-12 1998-05-22 The Regents Of The University Of California Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
DE19745950A1 (en) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Drug carrier particle for site specific drug delivery, especially to CNS
US6426086B1 (en) * 1998-02-03 2002-07-30 The Regents Of The University Of California pH-sensitive, serum-stable liposomes
US6372720B1 (en) 1998-02-05 2002-04-16 Kenneth J. Longmuir Liposome fusion and delivery vehicle
US7087770B2 (en) 1998-05-16 2006-08-08 Mirus Bio Corporation Compound containing a labile disulfide bond
US6936729B2 (en) * 1998-05-16 2005-08-30 Mirus Bio Corporation Compound containing a labile disulfide bond
KR100679906B1 (en) * 1998-09-16 2007-02-07 알자 코포레이션 Liposome-entrapped topoisomerase inhibitors
CA2353593A1 (en) * 1998-12-18 2000-06-22 Hadasit Medical Research Services & Development Ltd. Method of administering a compound to multi-drug resistant cells
US6379698B1 (en) * 1999-04-06 2002-04-30 Isis Pharmaceuticals, Inc. Fusogenic lipids and vesicles
US6613352B2 (en) 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
US6852334B1 (en) * 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
EP1173600A2 (en) * 1999-04-20 2002-01-23 The University Of British Columbia Cationic peg-lipids and methods of use
WO2000064483A2 (en) * 1999-04-23 2000-11-02 Alza Corporation Releasable linkage and compositions containing same
CA2369595C (en) * 1999-04-23 2010-10-05 Alza Corporation Conjugate having a cleavable linkage for use in a liposome
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
AUPQ014699A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using nanoparticles
AUPQ014799A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
JP2003501631A (en) * 1999-05-27 2003-01-14 ツェプトゼンス アクチエンゲゼルシャフト Functionalized vesicles
CN1193059C (en) * 1999-07-14 2005-03-16 阿尔萨公司 Neutral lipopolymer and liposomal compositions contg. same
AU7868400A (en) 1999-10-08 2001-04-23 Alza Corporation Neutral-cationic lipid for nucleic acid and drug delivery
US20040197390A1 (en) * 2001-05-29 2004-10-07 Shi-Kun Huang Neutral-cationic lipid for systemic delivery of factor VIII gene
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US6916488B1 (en) * 1999-11-05 2005-07-12 Biocure, Inc. Amphiphilic polymeric vesicles
DE60041351D1 (en) * 1999-11-24 2009-02-26 Transave Inc GSSYTEM
AU2136501A (en) * 1999-12-10 2001-06-18 Celator Technologies Inc. Lipid carrier compositions with protected surface reactive functions
DE60110057T2 (en) * 2000-01-28 2005-09-08 Alza Corp., Mountain View LIPOSOMES INCLUDED AN INCLUDED CONNECTION IN OUTSTANDING SOLUTION
AU2001254548B2 (en) * 2000-04-20 2006-09-28 The University Of British Columbia Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
US10293056B1 (en) * 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
BRPI0111220B8 (en) * 2000-06-02 2021-07-27 Univ Texas drug conjugates with ethylenedicysteine (ec)
USRE43612E1 (en) 2000-10-10 2012-08-28 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
EP1341497A4 (en) * 2000-11-02 2005-10-19 Smithkline Beecham Corp Receptor antagonist-lipid conjugates and delivery vehicles containing same
US6613280B2 (en) 2001-03-20 2003-09-02 Therox, Inc. Disposable cartridge for producing gas-enriched fluids
US20030003114A1 (en) * 2001-03-22 2003-01-02 Pan Xing Qing Enzyme-based anti-cancer compositions and methods
IL158160A0 (en) * 2001-03-26 2004-03-28 Alza Corp Liposome composition for improved intracellular delivery of a therapeutic agent
AU2002256398A2 (en) * 2001-04-30 2002-11-11 Targeted Genetics Corporation Lipid-comprising drug delivery complexes and methods for their production
US20050176025A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
US20050233997A1 (en) * 2001-05-18 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US20050288242A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
US20050159382A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US20050124566A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
US20050196765A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
JP4358521B2 (en) * 2001-05-18 2009-11-04 サーナ・セラピューティクス・インコーポレイテッド Conjugates and compositions for cellular delivery
US20050158735A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of proliferating cell nuclear antigen (PCNA) gene expression using short interfering nucleic acid (siNA)
US20050203040A1 (en) * 2001-05-18 2005-09-15 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US20050196767A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
AU2002329176A1 (en) * 2001-05-25 2002-12-23 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
US6939564B2 (en) * 2001-06-08 2005-09-06 Labopharm, Inc. Water-soluble stabilized self-assembled polyelectrolytes
WO2004033620A2 (en) 2001-11-02 2004-04-22 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
GB0129121D0 (en) * 2001-12-05 2002-01-23 Ic Vec Ltd Compound
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20030170299A1 (en) * 2002-02-27 2003-09-11 Lee Robert J. Therapeutic methods for acute myeloid leukemia
US7018655B2 (en) * 2002-03-18 2006-03-28 Labopharm, Inc. Amphiphilic diblock, triblock and star-block copolymers and their pharmaceutical compositions
WO2003083443A2 (en) * 2002-03-29 2003-10-09 University Of Florida Lipid mediated screening of drug candidates for identification of active compounds
AU2003278691A1 (en) * 2002-04-23 2004-02-02 The Research Foundation Of State University Of New York Polymer surfactants for gene therapy applications
JP3415131B1 (en) * 2002-06-03 2003-06-09 メビオファーム株式会社 Liposome preparation
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
US20040093198A1 (en) * 2002-11-08 2004-05-13 Carbon Design Systems Hardware simulation with access restrictions
CA2509939C (en) 2003-01-06 2013-05-21 Nektar Therapeutics Al, Corporation Thiol-selective water-soluble polymer derivatives
WO2004063216A1 (en) * 2003-01-10 2004-07-29 Yamanouchi Pharmaceutical Co., Ltd. Conjugate for retention in blood and cancer tissue-specific drug delivery
US20040213835A1 (en) * 2003-02-28 2004-10-28 Samuel Zalipsky Method to reduce liposome-induced complement activation
AU2004227847A1 (en) 2003-03-31 2004-10-21 Alza Corporation Lipid particles having asymmetric lipid coating and method of preparing same
KR20060015265A (en) * 2003-05-30 2006-02-16 알자 코포레이션 Method of pulmonary administration of an agent
US11324698B2 (en) 2003-08-28 2022-05-10 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
US8846079B1 (en) * 2004-12-01 2014-09-30 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
CA2560901C (en) * 2003-08-29 2012-08-21 The University Of Newcastle Research Associates Limited Stimulant sensitive flocculation and consolidation
US7943179B2 (en) 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
US20050175683A1 (en) * 2003-10-24 2005-08-11 Yuanpeng Zhang Preparation of lipid particles
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
JP2007520481A (en) * 2004-01-15 2007-07-26 アルザ・コーポレーシヨン Liposome composition for delivering therapeutic agents
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
US8168222B2 (en) 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
JP2008515929A (en) * 2004-10-08 2008-05-15 アルザ コーポレイション A method for inserting a lipid assembly into which a lipid linking part is preformed using microwaves
EP1854807A4 (en) * 2005-02-18 2009-04-01 Univ Tokushima Polyoxyalkylene chain-containing lipid derivative and lipid film structure containing such derivative
JP2006248978A (en) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd New liposome preparation
JP2008542270A (en) * 2005-05-23 2008-11-27 エスデイージー・インコーポレーテツド Lipid constructs for delivering interferon to mammals
EP1891141B1 (en) 2005-05-31 2016-11-16 Ecole Polytechnique Fédérale de Lausanne (EPFL) Triblock copolymers for cytoplasmic delivery of gene-based drugs
EP3067047B1 (en) 2005-12-08 2022-04-20 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
US8758723B2 (en) 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
EP2032652A4 (en) 2006-06-05 2011-08-17 Massachusetts Inst Technology Crosslinked, degradable polymers and uses thereof
US20080031883A1 (en) * 2006-07-13 2008-02-07 Torchilin Vladimir P Condition-dependent, multiple target delivery system
US8343539B2 (en) * 2006-07-14 2013-01-01 Regents Of The University Of Minnesota Compounds that bind α5β1 integrin and methods of use
EP2046266A4 (en) 2006-07-21 2009-11-04 Massachusetts Inst Technology End-modified poly(beta-amino esters) and uses thereof
US20080213349A1 (en) * 2006-09-11 2008-09-04 Deepak Ramesh Thakker Liposome Complexes Containing Pharmaceutical Agents and Methods
BRPI0716890A2 (en) * 2006-09-22 2013-10-22 Labopharm Inc COMPOSITION, AND METHOD OF PRODUCTION OF A COMPOSITION, ADMINISTRATION OF A PHARMACEUTICALLY ACTIVE WATER INSOLUBLE AGENT TO A MAMMER, AND CANCER TREATMENT IN A MAMMER
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US20100210575A1 (en) * 2007-06-29 2010-08-19 Wisconsin Alumni Research Foundation Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals
US20110105995A1 (en) * 2008-01-16 2011-05-05 Zhu Ting F Uniform-sized, multi-drug carrying, and photosensitive liposomes for advanced drug delivery
WO2009154688A1 (en) * 2008-05-28 2009-12-23 President And Fellows Of Harvard College A pre-fabricated electron microscopy grid for monolayer purification and methods and kits therefor
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
KR101647334B1 (en) * 2008-07-10 2016-08-10 세리나 쎄라퓨틱스, 인코포레이티드 Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US9271929B2 (en) 2008-11-25 2016-03-01 École Polytechnique Fédérale De Lausanne (Epfl) Block copolymers and uses thereof
EP2671888A1 (en) 2008-12-23 2013-12-11 Gilead Pharmasset LLC 3',5'-cyclic nucleoside phosphate analogues
CA2748057C (en) 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
NZ617066A (en) 2008-12-23 2015-02-27 Gilead Pharmasset Llc Nucleoside analogs
EP2230515B1 (en) * 2009-03-16 2014-12-17 Agilent Technologies, Inc. Passivation of surfaces after ligand coupling
NZ596186A (en) 2009-05-05 2014-03-28 Alnylam Pharmaceuticals Inc Lipid compositions
TWI576352B (en) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US9937128B2 (en) * 2009-08-03 2018-04-10 The University Of North Carolina At Chapel Hill Liposomes comprising a calcium phosphate-containing precipitate
PT2474306T (en) 2009-08-31 2016-12-07 Nanocarrier Co Ltd Particle composition and medicinal composition comprising same
AU2010326132B9 (en) 2009-12-01 2014-10-02 Translate Bio, Inc. Delivery of mRNA for the augmentation of proteins and enzymes in human genetic diseases
JP4829351B2 (en) 2010-02-05 2011-12-07 ナノキャリア株式会社 Easily disintegrating polymer micelle composition
JP5872539B2 (en) 2010-03-31 2016-03-01 ギリアド ファーマセット エルエルシー Purine nucleoside phosphoramidate
PL3290428T3 (en) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
CL2011000716A1 (en) 2010-03-31 2012-04-20 Gilead Pharmasset Llc Crystalline forms 1 6 of (s) -isopropyl-2 - (((s) - (((2r.3r.4r.5r) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2h) -yl) -4-fluoro-3-hydroxy-4-methyl tetrahydrofuran-2-yl) methoxy) (phenoxy) phosphoryl) amino) propanoate; pharmaceutical composition and combination; and its use to treat a hepatitis c virus infection.
CA2798273A1 (en) 2010-05-04 2011-11-10 Merrimack Pharmaceuticals, Inc. Antibodies against epidermal growth factor receptor (egfr) and uses thereof
WO2011160110A1 (en) 2010-06-19 2011-12-22 Western University Of Health Sciences Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics
EP2609135A4 (en) 2010-08-26 2015-05-20 Massachusetts Inst Technology Poly(beta-amino alcohols), their preparation, and uses thereof
EP3327125B1 (en) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
DK2691443T3 (en) 2011-03-28 2021-05-03 Massachusetts Inst Technology CONJUGIATED LIPOMERS AND USES OF THESE
DK2706988T3 (en) * 2011-05-12 2020-01-20 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd LIPOSOMES COMPREHENSIVE POLYMER CONJUGATED LIPIDS AND RELATED USE
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
KR102128248B1 (en) 2011-06-08 2020-07-01 샤이어 휴먼 지네틱 테라피즈 인크. Lipid nanoparticle compositions and methods for mrna delivery
US8883989B2 (en) 2011-10-18 2014-11-11 Regents Of The University Of Minnesota Fractalkine binding polynucleotides and methods of use
UA119028C2 (en) 2011-10-27 2019-04-25 Массачусеттс Інстітьют Оф Текнолоджі N-terminal functionalized amino acid derivatives capable of forming microspheres encapsulating the drug
US20150267192A1 (en) 2012-06-08 2015-09-24 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
CA2879139C (en) 2012-07-18 2021-05-11 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
CN102920658B (en) * 2012-11-02 2015-01-21 艾韦特(溧阳)医药科技有限公司 Liposome combined with GLP-1 (Glucagon-Like Peptide-1) analogue and polyethylene glycol and preparation method of liposome
RU2675859C2 (en) 2012-11-29 2018-12-25 Инсмед Инкорпорейтед Stabilised vancomycin formulations
US20140271822A1 (en) * 2013-03-13 2014-09-18 Mallinckrodt Llc Modified docetaxel liposome formulations
KR20150128687A (en) 2013-03-14 2015-11-18 샤이어 휴먼 지네틱 테라피즈 인크. Methods for purification of messenger rna
BR112015022868B1 (en) 2013-03-14 2023-05-16 Ethris Gmbh CFTR MRNA COMPOSITIONS AND RELATED USES AND METHODS
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
WO2015013510A1 (en) 2013-07-25 2015-01-29 Ecole Polytechnique Federale De Lausanne Epfl High aspect ratio nanofibril materials
EP3060258A1 (en) 2013-10-22 2016-08-31 Shire Human Genetic Therapies, Inc. Mrna therapy for phenylketonuria
PE20161242A1 (en) 2013-10-22 2016-12-11 Massachusetts Inst Technology LIPID FORMULATIONS FOR THE ADMINISTRATION OF MESSENGER RNA
EP3501605B1 (en) 2013-10-22 2023-06-28 Translate Bio, Inc. Mrna therapy for argininosuccinate synthetase deficiency
AU2014348683B2 (en) 2013-11-18 2020-11-05 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
FI3690056T3 (en) 2014-01-31 2023-03-19 Factor Bioscience Inc Methods and products for nucleic acid production and delivery
EP3583946A1 (en) 2014-04-01 2019-12-25 Rubius Therapeutics, Inc. Enucleated hematopoietic cells comprising an exogenous antigen
AU2015249312B2 (en) 2014-04-25 2021-07-29 Translate Bio, Inc. Methods for purification of messenger RNA
PT3142643T (en) 2014-05-15 2019-10-28 Insmed Inc Methods for treating pulmonary non-tuberculous mycobacterial infections
AU2015266764B2 (en) 2014-05-30 2019-11-07 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
WO2015200465A1 (en) 2014-06-24 2015-12-30 Shire Human Genetic Therapies, Inc. Stereochemically enriched compositions for delivery of nucleic acids
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
CN104546722B (en) * 2015-02-10 2017-05-24 中国医学科学院医药生物技术研究所 Miriplatin lipidosome and preparation method thereof
AU2016218977C1 (en) 2015-02-13 2023-03-23 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CA2990172A1 (en) 2015-06-19 2016-12-22 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
CN107920964B (en) 2015-07-09 2022-02-25 加利福尼亚大学董事会 Fusogenic liposome-coated porous silicon nanoparticles
US10517823B1 (en) * 2016-08-10 2019-12-31 Verily Life Sciences Llc ROS—responsive liposomes for specific targeting
US10583083B1 (en) 2016-08-10 2020-03-10 Verily Life Sciences Llc ROS-responsive multilamellar liposomal vesicles for targeting inflammatory macrophages
CN116115629A (en) 2016-08-17 2023-05-16 菲克特生物科学股份有限公司 Nucleic acid products and methods of administration thereof
CN109996809A (en) 2016-11-14 2019-07-09 诺华股份有限公司 Composition relevant to fusogenic protein MINION, method and therapeutical uses
EP3585417B1 (en) 2017-02-27 2023-02-22 Translate Bio, Inc. Method of making a codon-optimized cftr mrna
US11260132B2 (en) 2017-03-16 2022-03-01 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
CA3060442A1 (en) * 2017-04-19 2018-10-25 Apa- Advanced Technologies Ltd. Fusogenic liposomes, compositions, kits and use thereof for treating cancer
CA3063531A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
EP3700965A1 (en) 2017-10-27 2020-09-02 Massachusetts Institute of Technology Poly (beta-amino esters) and uses thereof
EP3773505A4 (en) 2018-03-30 2021-12-22 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
WO2020041793A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
CA3117914A1 (en) * 2018-10-24 2020-04-30 Apa- Advanced Technologies Ltd. Fusogenic liposomes for selective imaging of tumor cells
WO2020086965A1 (en) 2018-10-26 2020-04-30 Massachusetts Institute Of Technology Polymer-lipids and compositions
WO2023210671A1 (en) * 2022-04-26 2023-11-02 京セラ株式会社 Copolymer, polymer film, measuring device, and support for measurement

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0354855A2 (en) * 1988-08-11 1990-02-14 Terumo Kabushiki Kaisha Liposomes on which adsorption of proteins is inhibited
WO1991005545A1 (en) * 1989-10-20 1991-05-02 Liposome Technology, Inc. Liposome microreservoir composition and method
EP0526700A2 (en) * 1991-05-23 1993-02-10 Mitsubishi Chemical Corporation Drug-containing protein-bonded liposome
JPH07173079A (en) * 1992-12-22 1995-07-11 Nippon Oil & Fats Co Ltd Amphiphatic polyethylene glycol derivative and its use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136095A (en) * 1987-05-19 1992-08-04 Syntex (U.S.A.) Inc. Reversible agglutination mediators
US5620689A (en) * 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0354855A2 (en) * 1988-08-11 1990-02-14 Terumo Kabushiki Kaisha Liposomes on which adsorption of proteins is inhibited
WO1991005545A1 (en) * 1989-10-20 1991-05-02 Liposome Technology, Inc. Liposome microreservoir composition and method
EP0526700A2 (en) * 1991-05-23 1993-02-10 Mitsubishi Chemical Corporation Drug-containing protein-bonded liposome
JPH07173079A (en) * 1992-12-22 1995-07-11 Nippon Oil & Fats Co Ltd Amphiphatic polyethylene glycol derivative and its use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 9536, Derwent World Patents Index; AN 95-272844, XP002064708 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227917B2 (en) 2012-08-13 2016-01-05 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof

Also Published As

Publication number Publication date
DE69718924T2 (en) 2003-12-04
CA2267904C (en) 2005-08-02
ES2191833T3 (en) 2003-09-16
DE69718924D1 (en) 2003-03-13
AU715063B2 (en) 2000-01-13
EP0932391B1 (en) 2003-02-05
IL129292A0 (en) 2000-02-17
DK0932391T3 (en) 2003-05-26
JP2001504093A (en) 2001-03-27
ATE232086T1 (en) 2003-02-15
EP0932391A2 (en) 1999-08-04
US5891468A (en) 1999-04-06
BR9712230A (en) 2000-01-25
WO1998016202A2 (en) 1998-04-23
PT932391E (en) 2003-06-30
CA2267904A1 (en) 1998-04-23
AU4987897A (en) 1998-05-11
HK1047550A1 (en) 2003-02-28
TW520297B (en) 2003-02-11

Similar Documents

Publication Publication Date Title
WO1998016202A3 (en) Fusogenic liposome composition and method
AU1742597A (en) A hydrophilic, graphite fuel cell electrode for use with an ionomer membrane and method of making a fuel cell
MY122195A (en) New controlled release bead, a method of producing the same and multiple unit formulation comprising it
HK1021320A1 (en) Liposomes containing a cisplatin compound
WO2001057940A3 (en) Freestanding microporous separator including a gel-forming polymer
CA2235193A1 (en) Composite membranes
WO1999005126A8 (en) Perfluorovinyl ionic compounds and their use in conductive materials
AU1406897A (en) New polymer material for electrolytic membranes in fuel cells
EP0861804A4 (en) Cathode material for lithium secondary battery, process for manufacturing the same, and secondary battery using the same
AU4800497A (en) Tubular polymer electrolyte fuel cell assembly and method of manufacture
AU9210198A (en) Composite solid polymer electrolyte membranes
EP0903796A4 (en) Anode active material, its producing process, and lithium ion secondary cell using the anode active material
MXPA02004574A (en) New controlled release bead, a method of producing the same and multiple unit formulation comprising it.
AU6266398A (en) Method of preparing electrochemical cells
AU3171399A (en) Solid electrolyte fuel cell and method of producing the same
AU7171896A (en) Electrode plate for secondary battery with nonaqueous electrolyte and method of manufacturing the same
AU4451597A (en) An electrolyte system, a method for the preparation thereof, the use thereof and a battery containing the electrolyte system
AU2124495A (en) Bipolar battery cells, batteries, and methods
AU6354196A (en) A wound electrochemical cell, a method for the manufacture thereof, and the use of such electrochemical cells
GB2327294B (en) An active material for a cathode of lithium ion battery and a method for preparing the same
EP0845824B8 (en) Lithium secondary battery and cathode active material for use in lithium secondary battery
AU7277598A (en) Energy delivery of catheter and method for the use thereof
EP0971426B8 (en) Polymer secondary battery and method of making same
EP1214935A3 (en) Fusogenic liposome composition and method
AU1226699A (en) Composite suitable for use in electrochemical cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2267904

Country of ref document: CA

Ref country code: CA

Ref document number: 2267904

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 518629

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/003336

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1997912775

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997912775

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1997912775

Country of ref document: EP